Objectives: To explore the association between xerodema pigmentosum group D (XPD) Asp312Asn and Lys751Gln and apurinic apyrimidic endonuclease 1 (APE1) Asp148Glu gene polymorphism and risk of bladder cancer (BC) susceptibility. Methods: This hospital-based case-control study included 206 patients with newly diagnosed bladder transitional cell carcinoma and 250 cancer-free controls who had been frequency matched by age, sex, and ethnicity. Polymorphisms in XPD Asp312Asn and Lys751Gln and APE1 Asp148Glu gene using polymerase chain reaction-restriction fragment length polymorphism and amplification refractory mutation system were genotyped. Results: The XPD Asp312Asn AA genotype was associated with an elevated risk of BC (odds ratio [OR] 3.30, P = .001.) The AA genotype was significantly associated with nonmuscle-invasive BC (OR 4.62, corrected P = .003). Both the heterozygous GA and the homozygous AA was associated with a greater risk of low-grade (grade 1) BC (OR 2.51, corrected P = .006 and OR 5.21, corrected P = .003, respectively). The APE1 GG genotype showed a decreased risk of BC (OR 0.27, P = .027.) Haplotype AC (codon 312A-codon 751C) of XPD demonstrated an association with a greater susceptibility to BC (OR 2.16, correct P = .0008). Conclusions: Reduced DNA repair capacity due to XPD Asp312Asn AA genotype might be a risk factor for BC. The AA genotype predisposed to a greater risk at the initial stage and grade of BC. The APE1 148GG genotype conferred a protective association with BC susceptibility. © 2009 Elsevier Inc. All rights reserved.